研究单位：[1]Beijing Anzehn hospital[2]Boston Scientific Corporation[3]Beijing Tongren Hospital, Capital Medical University,Beijing,China[4]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[5]Jiangsu Province Hospital,Nanjing,Jiangsu,China[6]The First Affiliated Hospital of Harbin Medicial University,Harbin,Jilin,China[7]Zhongshan Hospital Affiliated to Fudan University,Shanghai,Shanghai,China[8]West China Hospital, Sichuan University,Chengdu,Sichuan,China[9]Xiangya Hospital Central South University,Changsha,China[10]Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,China[11]Tianjin Medical University General Hospital,Tianjin,China
This clinical study is a prospective, non-randomized, multicenter study to demonstrate the acceptable safety and performance of angioplasty with the Ranger DCB in native femoropopliteal artery lesions. It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Ranger DCB catheter. Approximately 123 patients with femoropopliteal artery lesions will be enrolled. All lesions will be treated with the Ranger DCB. Up to 15 clinical sites located in China are expected to participate.
